Polymorphisms in human MDR1 (P-glycoprotein): Recent advances and clinical relevance

Clinical Pharmacology and Therapeutics

Volumn 75, Issue 1, 2004, Pages 13-33

  Marzolini, Catia ^b   Paus, Erik ^b   Buclin, Thierry ^b   Kim, Richard B ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTACID AGENT; ANTIARRHYTHMIC AGENT; ANTIBIOTIC AGENT; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ANTIEMETIC AGENT; ANTIFUNGAL AGENT; ANTIHYPERTENSIVE AGENT; ANTINEOPLASTIC AGENT; ANTIVIRUS AGENT; DACTINOMYCIN; DAUNORUBICIN; DRUG METABOLIZING ENZYME; ETOPOSIDE; GLUCOCORTICOID; GLYCOPROTEIN P; IMATINIB; IMMUNOSUPPRESSIVE AGENT; IRINOTECAN; IVERMECTIN; MITOMYCIN C; MITOXANTRONE; MULTIDRUG RESISTANCE PROTEIN 1; NEUROLEPTIC AGENT; OPIATE; PACLITAXEL; PROTEIN INHIBITOR; TENIPOSIDE; TOPOTECAN; UNINDEXED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ALLERGY; ANTIHYPERTENSIVE THERAPY; ANTIINFLAMMATORY ACTIVITY; ASIAN; BREAST CARCINOMA; CANCER CHEMOTHERAPY; CAUCASIAN; CROHN DISEASE; DEPRESSION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DISPOSITION; DRUG DISTRIBUTION; DRUG EFFECT; DRUG EXCRETION; DRUG SAFETY; DRUG TRANSPORT; ENVIRONMENTAL FACTOR; EPILEPSY; ETHNIC DIFFERENCE; GENE FREQUENCY; GENE LINKAGE DISEQUILIBRIUM; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; GENOTYPE PHENOTYPE CORRELATION; HAPLOTYPE; HEART TRANSPLANTATION; HUMAN; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; IN VIVO STUDY; INFECTION; INFLAMMATION; KIDNEY TUMOR; NEGRO; NEUROLOGIC DISEASE; NEUROTOXICITY; NONHUMAN; OUTCOMES RESEARCH; PARKINSON DISEASE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INDUCTION; PROTEIN LOCALIZATION; PROTEIN POLYMORPHISM; PROTEIN SYNTHESIS INHIBITION; REVIEW; RISK ASSESSMENT; STATISTICAL SIGNIFICANCE; ULCERATIVE COLITIS;

CONTINENTAL POPULATION GROUPS; GENES, MDR; HUMANS; P-GLYCOPROTEIN; POLYMORPHISM, GENETIC; SUBSTRATE SPECIFICITY;

EID: 1642523162     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clpt.2003.09.012     Document Type: Review

References (155)

1. Schinkel A.H. The physiological function of drug-transporting P-glycoproteins. Semin Cancer Biol. 8:1997;161-170.
2. van Helvoort A., Smith A.J., Sprong H., Fritzsche I., Schinkel A.H., Borst P., et al. MDR1 P-glycoprotein is a lipid translocase of broad specificity, while MDR3 P-glycoprotein specifically translocates phosphatidylcholine. Cell. 87:1996;507-517.
3. Higgins C.F., Gottesman M.M. Is the multidrug transporter a flippase? Trends Biochem Sci. 17:1992;18-21.
4. Juliano R.L., Ling V. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim Biophys Acta. 455:1976;152-162.
5. Ueda K., Cardarelli C., Gottesman M.M., Pastan I. Expression of a full-length cDNA for the human MDR1 gene confers resistance to colchicines, doxorubicin, and vinblastine. Proc Natl Acad Sci U S A. 84:1987;3004-3008.
6. Thiebaut F., Tsuruo T., Hamada H., Gottesman M.M., Pastan I., Willingham M.C. Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc Natl Acad Sci U S A. 84:1987;7735-7738.
7. Cordon-Cardo C., O'Brien J.P., Casals D., Rittman-Grauer L., Biedler J.L., Melamed M.R., et al. Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites. Proc Natl Acad Sci U S A. 86:1989;695-698.
8. Sugawara I., Kataoka I., Morishita Y., Hamada H., Tsuruo T., Itoyama S., Mari S. Tissue distribution of P-glycoprotein encoded by a multidrug-resistant gene as revealed by a monoclonal antibody MRP16. Cancer Res. 48:1988;1926-1929.
9. Klimecki W.T., Futscher B.W., Grogan T.M., Dalton W.S. P-glycoprotein expression and function in circulating blood cells from normal volunteers. Blood. 83:1994;2451-2458.
10. Ecker G., Huber M., Schmid D., Chiba P. The importance of a nitrogen atom in modulators of multidrug resistance. Mol Pharmacol. 56:1999;791-796.
11. Jette L., Murphy G.F., Leclerc J.M., Beliveau R. Interaction of drugs with P-glycoprotein in brain capillaries. Biochem Pharmacol. 50:1995;1701-1709.
12. Shapiro A.B., Ling V. The mechanism of ATP-dependent multidrug transport by P-glycoprotein. Acta Physiol Scand Suppl. 643:1998;227-234.
13. Wils P., Phung-Ba V., Warnery A., Lechardeur D., Raeissi S., Hidalgo I.J., et al. Polarized transport of docetaxel and vinblastine mediated by P-glycoprotein in human intestinal epithelial cell monolayers. Biochem Pharmacol. 48:1994;1528-1530.
14. Widmer N., Colombo S., Buclin T., Decosterd L.A. Functional consequence of MDR1 expression on imatinib intracellular concentrations. Blood. 102:2003;1142. [letter].
15. Arimori K., Kuroki N., Hidaka M., Iwakiri T., Yamsaki K., Okumura M., et al. Effect of P-glycoprotein modulator, cyclosporine A, on the gastrointestinal excretion of irinotecan and its metabolite SN-38 in rats. Pharm Res. 20:2003;910-917.
16. Relling M.V. Are the major effects of P-glycoprotein modulators due to altered pharmacokinetics of anticancer drugs? Ther Drug Monit. 18:1996;350-356.
17. Sparreboom A., van Asperen J., Mayer U., Schinkel A.H., Smit J.W., Meijer D.K., et al. Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine. Proc Natl Acad Sci U S A. 94:1997;2031-2035.
18. Kakumoto M., Sakaeda T., Takara K., Nakamura T., Kita T., Yagami T., et al. Effects of carvedilol on MDR1-mediated multidrug resistance comparison with verapamil . Cancer Sci. 94:2003;81-86.
19. Karlsson J., Kuo S.M., Ziemniak J., Artursson P. Transport of celiprolol across human intestinal epithelial (Caco-2) cells mediation of secretion by multiple transporters including P-glycoprotein . Br J Pharmacol. 110:1993;1009-1016.
20. Saeki T., Ueda K., Tanigawara Y., Hori R., Komano T. P-glycoprotein- mediated transcellular transport of MDR-reversing agents. FEBS Lett. 324:1993;99-102.
21. Soldner A., Benet L.Z., Mutschler E., Christians U. Active transport of the angiotensin-II antagonist losartan and its main metabolite EX 3174 across MDCK-MDR1 and caco-2 cell monolayers. Br J Pharmacol. 129:2000;1235-1243.
22. Katoh M., Nakajima M., Yamazaki H., Yokoi T. Inhibitory potencies of 1,4-dihydropyridine calcium antagonists to P-glycoprotein-mediated transport comparison with the effects on CYP3A4 . Pharm Res. 17:2000;1189-1197.
23. Wang E., Lew K., Barecki M., Casciano C.N., Clement R.P., Johnson W.W. Quantitative distinctions of active site molecular recognition by P-glycoprotein and cytochrome P450 3A4. Chem Res Toxicol. 14:2001;1596-1603.
24. Wetterich U., Spahn-Langguth H., Mutschler E., Terhaag B., Rosch W., Langguth P. Evidence for intestinal secretion as an additional clearance pathway of talinolol enantiomers concentration- and dose-dependent absorption in vitro and in vivo . Pharm Res. 13:1996;514-522.
25. Kakumoto M., Takara K., Sakaeda T., Tanigawara Y., Kita T., Okumura K. MDR1-mediated interaction of digoxin with antiarrhythmic or antianginal drugs. Biol Pharm Bull. 25:2002;1604-1607.
26. de Lannoy I.A., Silverman M. The MDR1 gene product P-glycoprotein mediates the transport of the cardiac glycoside digoxin. Biochem Biophys Res Commun. 189:1992;551-557.
27. Woodland C., Verjee Z., Giesbrecht E., Koren G., Ito S. The digoxin-propafenone interaction characterization of a mechanism using renal tubular cell monolayers . J Pharmacol Exp Ther. 283:1997;39-45.
28. Kim R.B., Wandel C., Leake B., Cvetkovic M., Fromm M.F., Dempsey P.J., et al. Interrelationship between substrates and inhibitors of human CYP3A and P-glycoprotein. Pharm Res. 16:1999;408-414.
29. Kim R.B. Drugs as P-glycoprotein substrates, inhibitors, and inducers. Drug Metab Rev. 34:2002;47-54.
30. Ueda K., Okamura N., Hirai M., Tanigawara Y., Saeki T., Kioka N., et al. Human P-glycoprotein transports cortisol, aldosterone, and dexamethasone, but not progesterone. J Biol Chem. 267:1992;24248-24252.
31. Lin J.H., Chiba M., Chen I.W., Nishime J.A., deLuna F.A., Yamazaki M., et al. Effect of dexamethasone on the intestinal first-pass metabolism of indinavir in rats evidence of cytochrome P-450 A and P-glycoprotein induction . Drug Metab Dispos. 27:1999;1187-1193.
32. Saitoh H., Hatakeyama M., Eguchi O., Oda M., Takada M. Involvement of intestinal P-glycoprotein in the restricted absorption of methylprednisolone from rat small intestine. J Pharm Sci. 87:1998;73-75.
33. Wu X., Whitfield L.R., Stewart B.H. Atorvastatin transport in the Caco-2 cell model contributions of P-glycoprotein and the proton-monocarboxylic acid transporter . Pharm Res. 17:2000;209-215.
34. Boyd R.A., Stern R.H., Stewart B.H., Wu X., Reyner E.L., Zegarac E.A., et al. Atorvastatin coadministration may increase digoxin concentrations by inhibition of intestinal P-glycoprotein-mediated secretion. J Clin Pharmacol. 40:2000;91-98.
35. Orlowski S., Valente D., Garrigos M., Ezan E. Bromocriptine modulates P-glycoprotein function. Biochem Biophys Res Commun. 244:1998;481-488.
36. Verstuyft C., Strabach S., El-Morabet H., Kerb R., Brinkmann U., Dubert L., et al. Dipyridamole enhances digoxin bioavailability via P-glycoprotein inhibition. Clin Pharmacol Ther. 73:2003;51-60.
37. Cvetkovic M., Leake B., Fromm M.F., Wilkinson G.R., Kim R.B. OATP and P-glycoprotein transporters mediate the cellular uptake and excretion of fexofenadine. Drug Metab Dispos. 27:1999;866-871.
38. Didier A.D., Loor F. Decreased biotolerability for ivermectin and cyclosporine A in mice exposed to potent P-glycoprotein inhibitors. Int J Cancer. 63:1995;263-267.
39. Schinkel A.H., Wagenaar E., Mol C.A., van Deemter L. P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs. J Clin Invest. 97:1996;2517-2524.
40. Pham Y.T., Regina A., Farinotti R., Couraud P., Wainer I.W., Roux F., et al. Interactions of racemic mefloquine and its enantiomers with P-glycoprotein in an immortalized rat brain capillary endothelial cell line, GPNT. Biochim Biophys Acta. 1524:2000;212-219.
41. Riffkin C.D., Chung R., Wall D.M., Zalcberg J.R., Cowman A.F., Foley M., et al. Modulation of the function of human MDR1 P-glycoprotein by the antimalarial drug mefloquine. Biochem Pharmacol. 52:1996;1545-1552.
42. Barnes K.M., Dickstein B., Cutler G.B.J., Fojo T., Bates S.E. Steroid transport, accumulation and antagonism of P-glycoprotein in multidrug resistant cells. Biochemistry. 35:1996;4820-4827.
43. Elhafny B., Chappey O., Piciotti M., Debray M., Boval B., Roux F. Modulation of P-glycoprotein activity by glial factors and retinoic acid in an immortalized rat brain microvessel endothelial cell line. Neurosci Lett. 236:1997;107-111.
44. Nakamura T., Kakumoto M., Yamashita K., Takara K., Tanigawara Y., Sakaeda T., et al. Factors influencing the prediction of steady state concentrations of digoxin. Biol Pharm Bull. 24:2001;403-408.
45. Smit J.W., Schinkel A.H., Muller M., Weert B., Meijer D.K. Contribution of the murine mdr1a P-glycoprotein to hepatobiliary and intestinal elimination of cationic drugs as measured in mice with an mdr1a gene disruption. Hepatology. 27:1998;1056-1063.
46. Polli J.W., Jarrett J.L., Studenberg S.D., Humphreys J.E., Dennis S.W., Brouwer K.R., et al. Role of P-glycoprotein on the CNS disposition of amprenavir (141W94), an HIV protease inhibitor. Pharm Res. 16:1999;1206-1212.
47. Perloff M.D., von Moltke L.L., Fahey J.M., Daily J.P., Greenblatt D.J. Induction of P-glycoprotein expression by HIV protease inhibitors in cell culture. AIDS. 14:2000;1287-1289.
48. Kim R.B., Fromm M.F., Wandel C., Leake B., Wood A.J.J., Roden D.M., et al. The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. J Clin Invest. 10:1998;289-294.
49. Choo E.F., Leake B., Wandel C., Imamura H., Wood A.J., Wilkinson G.R., et al. Pharmacological inhibition of P-glycoprotein transport enhances the distribution of HIV-1 protease inhibitors into brain and testes. Drug Metab Dispos. 28:2000;655-660.
50. Wakasugi H., Yano I., Ito T., Hashida T., Futami T., Nohara R., et al. Effect of clarithromycin on renal excretion of digoxin interaction with P-glycoprotein . Clin Pharmacol Ther. 64:1998;123-128.
51. Schuetz E.G., Yasuda K., Arimori K., Schuetz J.D. Human MDR1 and mouse mdr1a P-glycoprotein alter the cellular retention and disposition of erythromycin but not of retinoic acid or benzopyrene. Arch Biochem Biophys. 350:1998;340-347.
52. Ito T., Yano I., Tanaka K., Inui K.I. Transport of quinolone antibacterial drugs by human P-glycoprotein expressed in a kidney epithelial cell line LLC-PK1. J Pharmacol Exp Ther. 282:1997;955-960.
53. Schuetz E.G., Schinkel A.H., Relling M.V., Schuetz J.D. P-glycoprotein a major determinant of rifampicin-inducible expression of cytochrome P4503A in mice and humans . Proc Natl Acad Sci U S A. 93:1996;4001-4005.
54. Schuetz E.G., Beck W.T., Schuetz J.D. Modulators and substrates of P-glycoprotein and cytochrome P4503A coordinately up-regulate these proteins in human colon carcinoma cells. Mol Pharmacol. 49:1996;311-318.
55. Tamai I., Yamashita J., Kido Y., Ohnari A., Sai Y., Shima Y., et al. Limited distribution of new quinolone antibacterial agents into brain caused by multiple efflux transporters at the blood-brain barrier. J Pharmacol Exp Ther. 295:2000;146-152.
56. Kavallaris M., Madagiflio J., Norris M.D., Haber M. Resistance to tetracycline, a hydrophilic antibiotic is mediated by P-glycoprotein in human multidrug-resistant cells. Biochem Biophys Res Commun. 190:1993;79-85.
57. Miyama T., Takanaga H., Matsuo H., Yamano K., Yamamoto K., Iga T., et al. P-glycoprotein-mediated transport of itraconazole across the blood-brain barrier. Antimicrob Agents Chemother. 42:1998;1738-1744.
58. Takara K., Tanigawara Y., Komada F., Nishiguchi K., Sakaeda T., Okumura K., et al. Pharmacokinetic aspects of reversal effect of itraconazole on P-glycoprotein-mediated resistance of anticancer drugs. Biol Pharm Bull. 22:1999;1355-1359.
59. Paine M.F., Leung L.Y., Lim H.K., Liao K., Oganesian A., Zhang M.Y., et al. Identification of a novel route of extraction of sirolimus in human small intestine roles of metabolism and secretion . J Pharmacol Exp Ther. 301:2002;174-186.
60. Yacyshyn B.R., Bowen-Yacyshyn M.B., Pilarski L.M. Inhibition by rapamycin of P-glycoprotein 170-mediated export from normal lymphocytes. Scand J Immunol. 43:1996;449-455.
61. Saeki T., Ueda K., Tanigawara Y., Hori R., Komano T. Human P-glycoprotein transports cyclosporin A and FK506. J Biol Chem. 268:1993;6077-6080.
62. Kochi S., Takanaga H., Matsuo H., Naito M., Tsuruo T., Sawada Y. Effect of cyclosporine A or tacrolimus on the function of blood-brain barrier cells. Eur J Pharmacol. 372:1999;287-295.
63. Tai H.L. Technology evaluation Valspodar, Novartis AG . Curr Opin Mol Ther. 2:2000;459-467.
64. Uhr M., Steckler T., Yassouridis A., Holsboer F. Penetration of amitriptyline, but not of fluoxetine, into brain is enhanced in mice with blood-brain barrier deficiency due to mdr1a P-glycoprotein gene disruption. Neuropsychopharmacology. 22:2000;380-387.
65. Pariante C.M., Kim R.B., Makoff A., Kerwin R.W. Antidepressant fluoxetine enhances glucocorticoid receptor function in vitro by modulating membrane steroid transporters. Br J Pharmacol. 139:2003;1111-1118.
66. Weiss J., Gregor Dormann S.M., Martin-Facklam M., Kerpen C.J., Ketabi-Kiyanvash N., Haefeli W.E. Inhibition of P-glycoprotein by newer antidepressants. J Pharmacol Exp Ther. 305:2003;197-204.
67. Durr D., Stieger B., Kullak-Ublick G.A., Rentsch K.M., Steinert H.C., Meier P.J., et al. Intestinal P-glycoprotein/MDR1 and intestinal and hepatic CYP3A4. Clin Pharmacol Ther. 68:2000;598-604.
68. Saitoh H., Aungst B.J. Possible involvement of multiple P-glycoprotein-mediated efflux systems in the transport of verapamil and other organic cations across rat intestine. Pharm Res. 12:1995;1304-1310.
69. Maki N., Hafkemeyer P., Dey S. Allosteric modulation of human P-glycoprotein. Inhibition of transport by preventing substrate translocation and dissociation. J Biol Chem. 278:2003;18132-18139.
70. Tateishi T., Nakura H., Asoh M., Watanabe M., Tanaka M., Kumai T., et al. Multiple cytochrome P-450 subfamilies are co-induced with P-glycoprotein by both phenothiazine and 2-acetylaminofluorene in rats. Cancer Lett. 138:1999;73-79.
71. Potschka H., Fedrowitz M., Loscher W. P-glycoprotein-mediated efflux of phenobarbital, lamotrigine, and felbamate at the blood-brain barrier evidence from microdialysis experiments in rats . Neurosci Lett. 26:2002;173-176.
72. Collett A., Higgs N.B., Sims E., Rowland M., Warhurst G. Modulation of the permeability of H2 receptor antagonists cimetidine and ranitidine by P-glycoprotein in rat intestine and the human colonic cell line Caco-2. J Pharmacol Exp. 288:1999;171-178.
73. Callagan R., Riordan J.R. Synthetic and natural opiates interact with P-glycoprotein in multidrug-resistant cells. J Biol Chem. 268:1993;16059-16064.
74. Aquilante C.L., Letrent S.P., Pollack G.M., Brouwer K.L. Increased brain P-glycoprotein in morphine tolerant rats. Life Sci. 66:2000;47-51.
75. Kim R., Wilkinson G. Pharmacogenetics of drug transporters. Kalow W., Meyer U.A., Tyndale R.F. Pharmacogenomics. 2001;81-108 Marcel Dekker, New York.
76. Lankas G.R., Cartwright M.E., Umbenhauer D. P-glycoprotein deficiency in a subpopulation of CF-1 mice enhances avermectin-induced neurotoxicity. Toxicol Appl Pharmacol. 143:1997;357-365.
77. Lankas G.R., Wise L.D., Cartwright M.E., Pippert T., Umbenhauer D.R. Placental P-glycoprotein deficiency enhances susceptibility to chemically induced birth defects in mice. Reprod Toxicol. 12:1998;457-463.
78. Pippert T.R., Umbenhauer D.R. The subpopulation of CF-1 mice deficient in P-glycoprotein contains a murine retroviral insertion in the mdr1a gene. J Biochem Mol Toxicol. 15:2001;83-89.
79. Schinkel A., Mayer U., Wagenaar E., Mol C., van Deemter L., Smit J., et al. Normal viability and altered pharmacokinetics in mice lacking mdr1-type (drug-transporting) P-glycoproteins. Proc Natl Acad Sci U S A. 94:1997;4028-4033.
80. Lin J.H., Yamazaki M. Role of P-glycoprotein in pharmacokinetics. Clin Pharmacokinet. 42:2003;59-98.
81. Meerum Terwogt J., Malingre M., Beijnen J., ten Bokkel Huinink W., Rosing H., Koopman F., et al. Co-administration of cyclosporin A enables oral therapy with paclitaxel. Clin Cancer Res. 5:1999;3379-3384.
82. Mayer U., Wagenaar E., Beijnen J.H., Smit J.W., Meijer D.K., van Asperen J., et al. Substantial excretion of digoxin via the intestinal mucosa and prevention of long-term digoxin accumulation in the brain by the mdr1a P-glycoprotein. Br J Pharmacol. 119:1996;1038-1044.
83. Verschraagen M., Koks C., Schellens J., Beijnen J. P-glycoprotein system as a determinant of drug interactions the case of digoxin-verapamil . Pharmacol Res. 40:1999;301-306.
84. Pedersen K.E. Digoxin interaction the influence of quinidine and verapamil on pharmacokinetics and receptor binding of digitalis glycosides . Acta Med Scand. 697:1985;11-40.
85. Greiner B., Eichelbaum M., Fritz P., Kreichgauer H.P., von Richter O., Zundler J., et al. The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin. J Clin Invest. 104:1998;147-153.
86. Synold T.W., Dussault I., Forman B.M. The orphan nuclear receptor SXR coordinately regulates drug metabolism and efflux. Nat Med. 7:2001;584-590.
87. Panwala C.M., Jones J.C., Viney J.L. A novel model of inflammatory bowel disease mice deficient for the multiple drug resistance gene, mdr1a, spontaneously develop colitis . J Immunol. 161:1998;5733-5744.
88. Kioka N., Tsubota J., Kakehi Y., Komano T., Gottesman M.M., Pastan I., et al. P-glycoprotein gene (MDR1) cDNA from human adrenal normal P-glycoprotein carries Gly185 with an altered pattern of multidrug resistance . Biochem Biophys Res Commun. 162:1989;224-231.
89. Hoffmeyer S., Burk O., von Richter O., Arnold H., Brockmoller J., Johne A., et al. Functional polymorphisms of the human multidrug-resistance gene multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo . Proc Natl Acad Sci U S A. 97:2000;3473-3478.
90. Cascorbi I., Gerloff T., Johne A., Meisel C., Hoffmeyer S., Schwab M., et al. Frequency of single nucleotide polymorphisms in the P-glycoprotein drug transporter MDR1 gene in white subjects. Clin Pharmacol Ther. 69:2001;169-174.
91. Siegmund W., Ludwig K., Giessmann T., Dazert P., Schroeder E., Sperker B., et al. The effects of the human MDR1 genotype on the expression of duodenal P-glycoprotein and disposition of the probe drug talinolol. Clin Pharmacol Ther. 72:2002;572-583.
92. Gerloff T., Schaefer M., Johne A., Oselin K., Meisel C., Cascorbi I., et al. MDR1 genotypes do not influence the absorption of a single oral dose of 1 mg digoxin in healthy white males. Br J Clin Pharmacol. 54:2002;610-616.
93. Kim R., Leake B., Choo E., Dresser G., Kubba S., Schwarz U., et al. Identification of functionally variant MDR1 alleles among European Americans and African Americans. Clin Pharmacol Ther. 70:2001;189-199.
94. Mickley L.A., Lee J.S., Weng Z., Zhan Z., Alvarez M., Wilson W., et al. Genetic polymorphism in MDR-1 a tool for examining allelic expression in normal cells, unselected and drug-selected cell lines, and human tumors . Blood. 91:1998;1749-1756.
95. Ito S., Ieiri I., Tanabe M., Suzuki A., Higuchi S., Otsubo K. Polymorphism of the ABC transporter genes, MDR1, MRP1 and MRP2/cMOAT, in healthy Japanese subjects. Pharmacogenetics. 11:2001;175-184.
96. Tanabe M., Ieiri I., Nagata N., Inoue K., Ito S., Kanamori Y., et al. Expression of P-glycoprotein in human placenta relation to genetic polymorphism of the multidrug resistance (MDR)-1 gene . J Pharmacol Exp Ther. 297:2001;1137-1143.
97. Yamauchi A., Ieiri I., Kataoka Y., Tanabe M., Nishizaki T., Oishi R., et al. Neurotoxicity induced by tacrolimus after liver transplantation relation to genetic polymorphisms of the ABCB1 (MDR1) gene . Transplantation. 74:2002;571-578.
98. Goto M., Masuda S., Saito H., Uemoto S., Kiuchi T., Tanaka K., et al. C3435T polymorphism in the MDR1 gene affects the enterocyte expression level of CYP3A4 rather than Pgp in recipients of living-donor liver transplantation. Pharmacogenetics. 12:2002;451-457.
99. Tang K., Ngoi S., Gwee P., Chua J., Lee E., Chong S., et al. Distinct haplotype profiles and strong linkage disequilibrium at the MDR1 multidrug transporter gene locus in three ethnic Asian populations. Pharmacogenetics. 12:2002;437-450.
100. Illmer T., Schuler U., Thiede C., Schwarz U., Kim R., Gotthard S., et al. MDR1 gene polymorphisms affect therapy outcome in acute myeloid leukemia patients. Cancer Res. 62:2002;4955-4962.
101. Horinouchi M., Sakaeda T., Nakamura T., Morita Y., Tamura T., Aoyama N., et al. Significant genetic linkage of MDR1 polymorphisms at positions 3435 and 2677 functional relevance to pharmacokinetics of digoxin . Pharm Res. 19:2002;1581-1585.
102. Moriya Y., Nakamura T., Horinouchi M., Sakaeda T., Tamura T., Aoyama N., et al. Effects of polymorphisms of MDR1, MRP1, and MRP2 genes on their mRNA expression levels in duodenal enterocytes of healthy Japanese. Biol Pharm Bull. 25:2002;1356-1359.
103. Furuno T., Landi M.T., Ceroni M., Caporaso N., Bernucci I., Nappi G., et al. Expression polymorphism of the blood-brain barrier component P-glycoprotein (MDR1) in relation to Parkinson's disease. Pharmacogenetics. 12:2002;529-534.
104. Zheng H., Webber S., Zeevi A., Schuetz E., Zhang J., Lamba J., et al. The MDR1 polymorphisms at exons 21 and 26 predict steroid weaning in pediatric heart transplant patients. Human Immunology. 63:2002;765-770.
105. Johne A., Kopke K., Gerloff T., Mai I., Rietbrock S., Meisel C., et al. Modulation of steady-state kinetics of digoxin by haplotypes of the P-glycoprotein MDR1 gene. Clin Pharmacol Ther. 72:2002;584-594.
106. Anglicheau D., Verstuyft C., Laurent-Puig P., Becquemont L., Schlageter M.H., Cassinat B., et al. Association of the multidrug resistance-1 gene single-nucleotide polymorphisms with the tacrolimus dose requirements in renal transplant recipients. J Am Soc Nephrol. 14:2003;1889-1896.
107. Gaikovitch E.A., Cascorbi I., Mrozikiewicz P.M., Brockmoller J., Frotschl R., Kopke K., et al. Polymorphisms of drug-metabolizing enzymes CYP2C9, CYP2C19, CYP2D6, CYP1A1, NAT2 and of P-glycoprotein in a Russian population. Eur J of Clin Pharmacol. 59:2003;303-312.
108. Schaeffeler E., Eichelbaum M., Brinkmann U., Penger A., Asante-Poku S., Zanger U.M., et al. Frequency of C3435T polymorphism of MDR1 gene in African people. Lancet. 358:2001;383-384.
109. Drozdzik M., Bialecka M., Mysliwiec K., Honczarenko K., Stankiewicz J., Sych Z. Polymorphism in the P-glycoprotein drug transporter MDR1 gene a possible link between environmental and genetic factors in Parkinson's disease . Pharmacogenetics. 13:2003;259-263.
110. Bernal M.L., Sinues B., Fanlo A., Mayayo E. Frequency distribution of C3435T mutation in exon 26 of the MDR1 gene in a Spanish population. Ther Drug Monit. 25:2003;107-111.
111. Siddiqui A., Kerb R., Weale M.E., Brinkmann U., Smith A., Goldstein D.B., et al. Association of multidrug resistance in epilepsy with a polymorphism in the drug-transporter gene ABCB1. N Engl J Med. 348:2003;1442-1448.
112. Ameyaw M.M., Regateiro F., Li T., Liu X., Tariq M., Mobarek A., et al. MDR1 pharmacogenetics frequency of the C3435T mutation in exon 26 is significantly influenced by ethnicity . Pharmacogenetics. 11:2001;217-221.
113. Roberts R.L., Joyce P.R., Mulder R.T., Begg E.J., Kennedy M.A. A common P-glycoprotein polymorphism is associated with nortriptyline-induced postural hypotension in patients treated for major depression. Pharmacogenomics J. 2:2002;191-196.
114. Sakaeda T., Nakamura T., Horinouchi M., Kakumoto M., Ohmoto N., Sakai T., et al. MDR1 genotype-related pharmacokinetics of digoxin after single oral administration in healthy Japanese subjects. Pharm Res. 18:2001;1400-1404.
115. Chowbay B., Cumaraswamy S., Cheung Y.B., Zhou Q., Lee E.J. Genetic polymorphisms in MDR1 and CYP3A4 genes in Asians and the influence of MDR1 haplotypes on cyclosporin disposition in heart transplant recipients. Pharmacogenetics. 13:2003;89-95.
116. Balram C., Sharma A., Sivathasan C., Lee E.J.D. Frequency of C3435T single nucleotide MDR1 genetic polymorphism in an Asian population phenotypic-genotypic correlates . Br J Clin Pharmacol. 56:2003;78-83.
117. Verstuyft C., Schwab M., Schaeffeler E., Kerb R., Brinkmann U., Jaillon P., et al. Digoxin pharmacokinetics and MDR1 genetic polymorphisms. Eur J Clin Pharmacol. 58:2003;809-812.
118. Kurata Y., Ieiri I., Kimura M., Morita T., Irie S., Urae A., et al. Role of human MDR1 gene polymorphism in bioavailability and interaction of digoxin, a substrate of P-glycoprotein. Clin Pharmacol Ther. 72:2002;209-219.
119. Drescher S., Schaeffeler E., Hitzl M., Hofmann U., Schwab M., Brinkmann U., et al. MDR1 gene polymorphisms and disposition of the P-glycoprotein substrate fexofenadine. Br J Clin Pharmacol. 53:2002;526-534.
120. Fellay J., Marzolini C., Meaden E., Back D., Buclin T., Chave J., et al. Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1 a pharmacogenetics study . Lancet. 359:2002;30-36.
121. von Ahsen N., Richter M., Grupp C., Ringe B., Oellerich M., Armstrong V.W. No influence of the MDR-1 C3435T polymorphism or a CYP3A4 promoter polymorphism (CYP3A4-V allele) on dose-adjusted cyclosporin A trough concentrations or rejection incidence in stable renal transplant recipients. Clin Chem. 47:2001;1048-1052.
122. Min D.I., Ellingrod V.L. C3435T mutation in exon 26 of the human MDR1 gene and cyclosporine pharmacokinetics in healthy subjects. Ther Drug Monit. 24:2002;400-404.
123. Yates C., Zhang W., Song P., Li S., Gaber A., Kotb M., et al. The effect of CYP3A5 and MDR1 polymorphic expression on cyclosporine oral disposition in renal transplant patients. J Clin Pharmacol. 43:2003;555-564.
124. Macphee I., Fredericks S., Tai T., Syrris P., Carter N., Johnston A., et al. Tacrolimus pharmacogenetics polymorphisms associated with expression of cytochrome P4503A5 and P-glycoprotein correlate with dose requirement . Transplantation. 74:2002;1486-1489.
125. Zheng H., Webber S., Zeevi A., Schuetz E., Zhang J., Bowman P., et al. Tacrolimus dosing in pediatric heart transplant patients is related to CYP3A5 and MDR1 gene polymorphisms. Am J Transplant. 3:2003;477-483.
126. Pauli-Magnus C., Feiner J., Brett C., Lin E.T., Kroetz D.L. No effect of MDR1 C3435T polymorphism on disposition and CNS effects of loperamide. Clin Pharmacol Ther. 73:2003;72. [abstract].
127. Putnam W., Desai D.G., Hung Y., Woo J.M., Benet L.Z. The effect of induction conditions and MDR1 genotypes on dicloxacillin pharmacokinetics. Clin Pharmacol Ther. 73:2003;57. [abstract].
128. Goh B.C., Lee S.C., Wang L.Z., Fan L., Guo J.Y., Lamba J., et al. Explaining interindividual variability of docetaxel pharmacokinetics and pharmacodynamics in Asians through phenotyping and genotyping strategies. J Clin Oncol. 20:2002;3683-3690.
129. Kerb R., Aynacioglu A.S., Brockmoller J., Schlagenhaufer R., Bauer S., Szekeres T., et al. The predictive value of MDR1, CYP2C9, and CUP2C19 polymorphisms for phenytoin plasma levels. Pharmacogenomics J. 1:2001;204-210.
130. Nakamura T., Sakaeda T., Horinouchi M., Tamura T., Aoyama N., Shirakawa T., et al. Effect of the mutation (C3435T) at exon 26 of the MDR1 gene on expression level of MDR1 messenger ribonucleic acid in duodenal enterocytes of healthy Japanese subjects. Clin Pharmacol Ther. 71:2002;297-303.
131. van der Heiden I.P., van der Heuvel M.M., Wiemer E., Pieters R., Lindemans J., van der Anker J., et al. MDR1 C3435T gene polymorphism does not correlate with P-gp expression and function in acute myeloid leukemia. Clin Pharmacol Ther. 73:2003;58. [abstract].
132. Hitzl M., Drescher S., van der Kuip H., Schaffeler E., Fischer J., Schwab M., et al. The C3435T mutation in the human MDR1 gene is associated with altered efflux of the P-glycoprotein substrate rhodamine 123 from CD56+ natural killer cells. Pharmacogenetics. 11:2001;293-298.
133. Oselin K., Gerloff T., Mrozikiewicz P.M., Pahkla R., Roots I. MDR1 polymorphisms G2677T in exon 21 and C3435T in exon 26 fail to affect rhodamine 123 efflux in peripheral blood lymphocytes. Fundam Clin Pharmacol. 17:2003;463-469.
134. Calado R.T., Falcao R.P., Garcia A.B., Gabellini S.M., Zago M.A., Franco R.F. Influence of functional MDR1 gene polymorphisms on P-glycoprotein activity in CD34+ hematopoietic stem cells. Haematologica. 87:2002;564-568.
135. Oselin K., Nowakowski-Gashaw I., Mrozikiewicz P.M., Wolbergs D., Pahkla R., Roots I. Quantitative determination of MDR1 mRNA expression in peripheral blood lymphocytes a possible role of genetic polymorphisms in the MDR1 gene . Eur J Clin Invest. 33:2003;261-267.
136. Morita N., Yasumori T., Nakayama K. Human polymorphism G2677T/A and C3435T have no effect on MDR1 transport activities . Biochem Pharmacol. 65:2003;1843-1852.
137. Kimchi-Sarfaty C., Gribar J.J., Gottesman M.M. Functional characterization of coding polymorphisms in the human MDR1 gene using a vaccinia virus expression system. Mol Pharmacol. 62:2002;1-6.
138. Siegsmund M., Brinkmann U., Schaffeler E., Weirich G., Schwab M., Eichelbaum M., et al. Association of the P-glycoprotein transporter MDR1 (C3435T) polymorphism with the susceptibility to renal epithelial tumors. J Am Soc Nephrol. 13:2002;1847-1854.
139. Efferth T., Sauerbrey A., Steinbach D., Gebhart E., Drexler H.G., Chitambar C.R., et al. Analysis of single nucleotide polymorphism C3435T of the multidrug resistance gene MDR1 in acute lymphoblastic leukemia. Int J Oncol. 23:2003;509-517.
140. Kafka A., Sauer G., Jaeger C., Grundmann R., Kreienberg R., Zeillinger R., et al. Polymorphism C3435T of the MDR-1 gene predicts response to preoperative chemotherapy in locally advanced breast cancer. Int J Oncol. 22:2003;1117-1121.
141. Schwab M., Schaeffeler E., Marx C., Fromm M.F., Kaskas B., Metzler J., et al. Association between the C3435T MDR1 gene polymorphism and susceptibility for ulcerative colitis. Gastroenterology. 124:2003;26-33.
142. Nasi M., Borghi V., Pinti M., Bellodi C., Lugli E., Maffei S., et al. MDR1 C3435T genetic polymorphism does not influence the response to antiretroviral therapy in drug-naive HIV-positive patients. AIDS. 17:2003;1696-1698.
143. Ifergan I., Bernard N.F., Bruneau J., Alary M., Tsoukas C.M., Roger M. Allele frequency of three functionally active polymorphisms of the MDR-1 gene in high-risk HIV-negative and HIV-positive Caucasians. AIDS. 16:2002;2340-2342.
144. Bleiber G, Suarez C, Martinez R, Fellay J, Marzolini C, May M, et al. Influence of MDR1 on CD4+ T-cell permissiveness to HIV-1 infection [abstract D-70]. In: Proceedings of the Tenth Conference on Retroviruses and Opportunistic Infections; 2003 Feb 10-14; Boston, Mass.
145. Brumme Z., Dong W.W.Y., Chan K.J., Hogg R.S., Montaner J.S.G., O'Shaughnessy M.V., et al. Influence of polymorphisms within the CX3CR1 and MDR-1 genes on initial antiretroviral therapy response. AIDS. 17:2003;201-208.
146. Longuemaux S., Delomenie C., Gallou C., Mejean A., Vincent-Viry M., Bouvier R., et al. Candidate genetic modifiers of individual susceptibility to renal cell carcinoma a study of polymorphic human xenobiotic-metabolizing enzymes . Cancer Res. 59:1999;2903-2908.
147. Lee C.G., Ramachandra M., Jeang K.T., Martin M.A., Pastan I., Gottesman M.M. Effect of ABC transporters on HIV-1 infection inhibition of virus production by the MDR1 transporter . FASEB J. 14:2000;516-522.
148. Speck R.R., Yu X.F., Hildreth J., Flexner C. Differential effects of P-glycoprotein and multidrug resistance protein-1 on productive human immunodeficiency virus infection. J Infect Dis. 186:2002;332-340.
149. Sparreboom A., Danesi R., Ando Y., Chan J., Figg W. Pharmacogenomics of ABC transporters and its role in cancer chemotherapy. Drug Resist Updat. 6:2003;71-84.
150. Shen L.X., Basilion J.P., Stanton V.P. Jr. Single-nucleotide polymorphisms can cause different structural folds of mRNA. Proc Natl Acad Sci U S A. 96:1999;7871-7876.
151. Frittitta L., Ercolino T., Bozzali M., Argiolas A., Graci S., Santagati M.G., et al. A cluster of three single nucleotide polymorphisms in the 3′-untranslated region of human glycoprotein PC-1 gene stabilizes PC-1 mRNA and is associated with increased PC-1 protein content and insulin resistance-related abnormalities. Diabetes. 50:2001;1952-1955.
152. Schuetz E.G., Umbenhauer D.R., Yasuda K., Brimer C., Nguyen L., Relling
153. Dresser G., Schwarz U., Wilkinson G., Kim R., Roden D. Fexofenadine bio-availability modulated by dietary salt. Clin Pharmacol Ther. 69:2001;23. [abstract].
154. Trambas C., Wang Z., Cianfriglia M., Woods G. Evidence that natural killer cells express mini P-glycoproteins but not classic 170 kDA P-glycoprotein. Br J Haematol. 114:2001;177-184.
155. Kroetz D.L., Pauli-Magnus C., Hodges L.M., Huang C.C., Kawamoto M., Johns S.J., et al. Sequence diversity and haplotype structure in the human ABCB1 (MDR1, multidrug resistance transporter) gene. Pharmacogenetics. 13:2003;481-494.